Skip to main content
SpringerLink
Log in

ICER releases revised report on crisaborole and dupilumab

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Midwest Comparative Effectiveness Public Advisory Council

Reference

  • Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Releases Revised Evidence Report on Dupilumab and Crisaborole for Treatment of Atopic Dermatitis. Internet Document : 12 May 2017. Available from: URL: https://icer-review.org/announcements/ad-evidence-report/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER releases revised report on crisaborole and dupilumab. PharmacoEcon Outcomes News 778, 5 (2017). https://doi.org/10.1007/s40274-017-3982-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3982-z

Search

Navigation